Personalis, Inc. is rated Buy due to strong momentum in its NeXT Personal Dx MRD test and recent expansions in Medicare coverage for cancer recurrence monitoring. The company targets 43,000 to 45,000 clinical tests this year despite a projected net loss of about $100 million in 2026 and 14% revenue growth. Key growth drivers include expanded CMS MolDX coverage for breast and lung cancer and potential merger and acquisition interest given its $887 million market cap. Risks involve dependence on major pharma clients, competition in the MRD testing market, and the challenge of achieving sustainable revenue growth amid ongoing losses.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
